BetterLife Provides Comments on CEO’s Share Position Ownership and Recent BCSC Press Release

Core Viewpoint - BetterLife Pharma Inc. is an emerging biotech company focused on developing BETR-001, a non-hallucinogenic neuroplastogen aimed at treating psychiatric and neurological disorders, and has issued a press release in response to the British Columbia Securities Commission's recent announcement [1]. Company Overview - BetterLife Pharma Inc. is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, for neuro-psychiatric and neurological disorders [3]. - BETR-001 is currently in preclinical and IND-enabling studies and is a non-controlled substance intended for treating major depressive disorder, anxiety disorder, and neuropathic pain [4]. - BETR-002, also in preclinical and IND-enabling studies, is based on honokiol and targets anxiety-related disorders, including benzodiazepine dependency [5]. Management Ownership Disclosure - The company amended its past Management Information Circulars to correct disclosures regarding the beneficial ownership of its CEO, Dr. Ahmad Doroudian, increasing his ownership from approximately 5.8 million shares to 16 million shares since early 2023 [2]. - The amended disclosures show significant increases in Dr. Doroudian's beneficial ownership percentages across various proposals, with the most notable change from 9.455% to 22.01% in February 2019 [2].